Tb assessment tool nsw health

The GDS is a brief scale that measures depression in geriatric populations. The GDS was developed as a item questionnaire but a item questionnaire was developed in and has been validated.

Due to its requirement to self-report symptoms over the previous week, the GDS is most appropriate for the early stages of dementia where potential problems with memory are less confounding. A short version, the GDS, has also been developed with similar psychometric properties to the original full version.

The HADS is a frequently used self-rating scale developed to assess psychological distress in non-psychiatric patients. It consists of 14 items with seven items for the anxiety subscale and seven for the depression subscale. HADS has been validated in many languages, countries and settings including hospital, general practice and community settings. The K10 is a simple measure of general distress without identifying its cause. It is a screening instrument to identify people in need of further assessment for anxiety and depression.

The K10 measurement of a client's psychological distress levels can also be used as an outcome measure and to assist in treatment planning and monitoring. Can be difficult to use with consumers with dementia.

This has nine items based on the client's feelings over the previous three days. By providing a structured interview guide inter-rater reliability can be improved. The NPI includes both symptom frequency and severity ratings.

The NPI has been very well validated and is highly popular worldwide. NPI test form. The PAS is a very brief measure of agitation that is particularly useful as an initial screen of BPSD in nursing home and hospital settings.

It measures the severity of agitation in four general categories: aberrant vocalisation, motor agitation, aggressiveness and resisting care.

The PAS has been frequently used to measure change in agitation following non-pharmacological interventions, and to distinguish people with dementia from those with depression. The RAGE is a very brief scale specifically designed to measure aggressive behaviour.

It was developed so that nurses could objectively measure aggressive behaviours in residential settings and to enable researchers to test the effects of therapeutic interventions. The RAGE has been shown to accurately detect clinically significant changes in aggressive behaviours over time, in a range of settings and in people with dementia.

There must be a three-day or week long observation period. It is very suitable for a nursing home settings. The RAID is a rating scale to measure anxiety in people with dementia. Scores on RAID have been shown to be unrelated to the level of dementia severity or cognitive impairment. The RAWS is a item tool. Values for each item range from 1 to 4: value 1 is assigned to the first response listed for each item and so on. A higher score indicates the person walks with greater intensity and exhibits more characteristics of wandering behavior than those with lower scores.

The responses can also be used to determine times of the day when the person is most active Q7, 8 and 9. The subscale with the highest average score indicates the characteristic of wandering of most concern for that individual and their care and support. The RAWS-CV has 39 items and six sub-scales to identify characteristics of wandering exhibited: persistent wailing, repetitive walking, eloping behaviour, spatial disorientation, negative outcomes and meal time impulsivity.

A higher score indicates the person walks with more intensity and exhibits more characteristics of wandering behavior. The responses can also be used to determine times of the day when the person is most active Q 8, 10 and The subscale with the highest average score indicates the characteristic of wandering of concern for that individual.

The SAD-Q was developed to assess depressed mood in aphasic clients in hospital and community settings. The VAMS is a brief measure of a patient's mood state and includes assessment of eight distinct moods: sad, afraid, tired, angry, confused, tense, happy and energetic. It is validated for use in neurological populations as well as neurotypical populations.

This tool was developed to link the deterioration of intelligence and personality with the underlying neuropathology in dementia. It looks at the biological, psychological and social changes in dementia. It involves the clinical rating of changes in activities of daily living, self-care abilities and behaviour.

Information is gained from relatives or friends in the preceding six months; yet medical records have also been used. Test available online. The CDR is a comprehensive dementia staging scale that has become a worldwide standard for assessing the severity and progression of dementia.

Two different scores can be calculated from the CDR: the Global score which is the standard regularly used in clinical and research settings but requires an algorithm to calculate the Sum of Boxes score which provides more comprehensive information, particularly in patients with mild dementia, and does not require an algorithm to calculate. Author and year Hughes et al, Licensing, fees or copyright details The CDR can be used without modification or editing of any kind solely for clinical-care purposes and non-commercial research.

For more information on permission and licensing, please visit the CDR website or the licensing page of the University of Washington in St.

The DSRS is a brief staging instrument that is completed by the carer. It has a multiple-choice format. The FAST is a very brief dementia staging scale with a focus on functional decline at the moderate to severe stages of dementia. It was developed by the makers of the Global Deterioration Scale. The GDS is a brief dementia staging scale designed for carers and clinical staff to assess the current stage of dementia and its progression over time.

The GDS has been extensively validated, and has a long history of use worldwide. This item screening tool has been developed to screen for risk of cognitive impairment in an Alcohol and Other Drugs AOD treatment population. If a person scores positive on the screening tool it is recommended the BEAT be administered. Population group: 18 years and older AOD treatment population.

Likely to be applicable to other settings but not yet trialled. For use in primary health, inpatient and outpatient settings. The BEAT is a cognitive test developed to detect cognitive impairment, especially executive function impairment, in an AOD treatment population.

Population group: 18 years and over. Requires a systematic assessment of: cultural identity cultural conceptualisations of distress, psychosocial stressors and cultural features of vulnerability and resilience cultural features of the relationship between the individual and clinician overall cultural assessment. The glossary contains cultural concepts of distress to describe ways that cultural groups experience, understand and communicate suffering, behavioural problems, or troubling thoughts and emotions.

The RUDAS is developed for the assessment of cognitive impairment and dementia in culturally and linguistically diverse CALD people, and in those with limited levels of education. It is easily translatable into different languages and has been shown to detect dementia regardless of the language spoken or the educational level of the person tested. The RUDAS is a short cognitive screening instrument that was designed to minimise the effects of educational level, cultural background, gender and language on cognitive screening.

The six-item RUDAS assesses multiple cognitive domains including memory, praxis, language, judgement, visuoconstructional drawing and body orientation. It is a validated tool, based on evidence from multiple studies conducted in , and Can be used in any clinical setting such as in-hospital, out-patient clinic and community-based. Also can be used in any clinical speciality but commonly used by geriatricians, psychogeriatricians, neuropsychologists and neurologists.

It is used in the Aged Care Application to assess eligibility for the Dementia and Cognition Supplement for in-home care in people that are from a culturally or linguistically diverse background. Administration and scoring guide. Further information from Dementia Australia. Instruction booklet. It is used in the Aged Care Application to assess eligibility for the Dementia and Cognition Supplement for in-home care in patients that are Indigenous Australians an Aboriginal person or Torres Strait Islander who lives in a rural or remote area.

The 4AT is designed to be used by any Healthcare professional at first contact with the patient, and at any other time when delirium is suspected. It is a short tool for delirium assessment, designed to be easy to use in clinical care and specifically for routine clinical practice. It is suitable for use by all practitioners with a basic knowledge of delirium.

All patients can be assessed, including those unable to speak e. Note that the 4AT is not designed for repeated two to three times per day monitoring for new onset delirium in inpatients.

The 4AT is one of the best-validated delirium assessment tools globally. The CAM is a structured questionnaire developed as a brief screen for delirium. It is designed for use in older people at high risk of developing delirium e. It can also distinguish people with delirium-only from those with delirium superimposed on dementia, a clinically important distinction since the latter strongly predicts a worse medical outcome.

When the CAM is used alongside cognitive testing the differential diagnosis of dementia from delirium can be enhanced. The CAM is very widely utilised and has been translated into several languages. A three-minute diagnostic version 3D-CAM has been validated. The DRS-R is recommended if more detailed testing is required. The DRAT is used to assess delirium risk for hospitalised older people and is performed in conjunction with cognitive screening.

This tool identifies key risk factors that predispose an older person to delirium and risk factors that may precipitate delirium and recommends further investigations, if there is a change in behaviour. Population group: for all people over 65 all over 45 ATSI or all with known predisposing factors and all with known related conditions.

The DRS-R is a comprehensive scale designed to measure delirium and its severity. It is a revised version of the original DRS scale and be applied to people with or without dementia.

It has excellent inter-rater reliability and can distinguish people with delirium versus illness due to other causes e. The DRS-R can also distinguish people with delirium-only from those with delirium superimposed on dementia, an extremely important distinction since the latter strongly predicts a more adverse medical outcome.

The DRS-R has been translated into several languages. For more rapid testing by non-specialists the CAM may be more appropriate. Answer sheet. Skip to main content Skip to main navigation. Home Resources Aged Health Screening and assessment tools. Screening and assessment tools for older people. This resource contains 55 screening and assessment tools relating to behaviour, cognition, delirium, dementia, depression, disability, multicultural tools and Aboriginal tools. Having a centralised list of tools will increase awareness among clinicians about what is available and will aid decision-making when choosing a tool for use.

Thank you to all those who contributed to the development of this resource. This test also forms part of the Mini-Cog tool. Original Cognistat: 20 mins. It is designed to be suitable to assess cognition in persons in nursing home settings. Variable: dependent on the severity of information processing difficulty and the complexity of tasks assessed.

A tester familiar with the PRPP can complete the assessment of one person on four or five tasks in hours. It is a version of the MMSE. It is designed for use in older people at high risk of developing delirium.

Author and year Teng and Chui, Licensing, fees or copyright details 3MS test and manual free of charge for qualified professionals. Materials can be downloaded after obtaining approval from the Alzheimer Disease Research Center at the University of Southern California. Training materials No formal training is needed; however it is recommended that the interviewer gain mastery over the administration and scoring of the instrument.

Archives of Neurology, 52 5 , — Teng, E. Journal of Clinical Psychiatry, 48 8 , — Tsoi, K. Author and year Hsieh et al. For other uses, please contact the original authors to seek permission. Reading: Tsoi, K. Copyright held by John Hodges. November International Journal of Geriatric Psychiatry. PMID D McRaithe et al. Author and year Gavin et al, Licensing, fees or copyright details The AD8 can be used without modification or editing of any kind solely for clinical care purposes and non-commercial research.

For more information on permission and licensing, please visit the AD8 website or the licensing page of the University of Washington in St. The AD8: a brief informant interview to detect dementia. Neurology, 65 4 , — Author and year Rosen et al, Licensing, fees or copyright details Free of charge to healthcare professionals for non-commercial clinical or research purposes.

Rosen, W. Am J Psychiatry, 11 : — Author and year Licensing, fees or copyright details Free. No permission or registration is required to download and use. Evaluation of a mental test score for assessment of mental impairment in the elderly.

Age and Ageing, Volume 1, Issue 4, , Pages — Piotrowicz et al, Validation of the Hodkinson abbreviated mental test as a screening instrument for dementia in an Italian population. Age Ageing. Screening for dementia in general hospital inpatients: a systematic review and meta-analysis of available instruments.

Construct validity of the item geriatric depression scale in older medical inpatients. J Geriatr Psychiatry Neurol. Licensing, fees or copyright details Training materials No formal training. The clock-drawing test: review. Age and Ageing ; Training materials Training media Time to administer Original Cognistat: 20 mins. Two additional four word lists are provided for the memory section.

Reading: Peer-reviewed articles. The FAB is a brief screen for executive dysfunction associated with damage to the frontal lobe. It can be administered in many settings and is well-accepted by consumers.

Author and year Dubois et al, Licensing, fees or copyright details Free of charge to healthcare professionals for non-commercial clinical or research purposes. The FAB: A frontal assessment battery at bedside. Neurology, 55 11 , — Arch Neurol. Nakaaki, S. Reliability and validity of the Japanese version of the Frontal Assessment Battery in patients with the frontal variant of frontotemporal dementia. Psychiatry and Clinical Neurosciences, 61 1 , 78— Journal of the American Geriatrics Society, 50 3 , — Brodaty, H.

International Journal of Geriatric Psychiatry, 19 9 , — American Journal of Geriatric Psychiatry, 14 5 , — Seeher, K. The informant or proxy rater needs to have known the patient for 10 years Sansoni, et al Author and year Jorm and Korten, Licensing, fees or copyright details Free of charge to healthcare professionals for non-commercial clinical or research purposes. Training materials A training video and guide is available Vertesi et al.

Readings: Jorm, A. International Psychogeriatrics, 16 3 , — Australian Health Services Research Institute, Butt Z and Butt Z Sensitivity of the informant questionnaire on cognitive decline: an application of item response theory. International Psychogeriatrics. Isella V, Villa L, Russo A, et al Discriminative and predictive power of an informant report in mild cognitive impairment.

Assessing older persons: measures, meaning and practical applications. Journal of Neurology. Reading: strokengine. Author and year Borson et al. Annual influenza vaccine is strongly recommended for all students and is a requirement for students attending placement in a Category A High Risk area.

Students attending placements in Category A High Risk positions must receive the current southern hemisphere influenza vaccine.

In order to ensure that NSW Health facilities are complying with these requirements the provisions have been included in the amended policy directive.

Workers who are unable to be vaccinated for influenza due to a medical contraindication as per the online Australian Immunisation Handbook must provide evidence of this from their medical practitioner. Workers employed in a NSW Health residential aged care facility, or those who routinely work in such facilities, who refuse to be vaccinated must not work in the facility while the legal requirement is in force if the vaccine is available to them.

These requirements have been included in the updated Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases policy directive to ensure consistency. The requirements relating to residential aged care facility workers are detailed in legislation Public Health COVID Residential Aged Care Facility Order and there are no allowances for workers who refuse vaccination, if the vaccine is available to them.

In an emergency situation, such as an ambulance call out, or where officers from Fire and Rescue NSW, or NSW Police Force are attending a RACF in an emergency, or where tradespeople are required to attend to urgent repairs, it is considered reasonable for the officers or tradesperson to attend even if they have not been screened or cannot show they have a flu vaccination.

If such personnel are attending the RACF in a non-emergency or non-urgent situations such as planned attendances , they must have been vaccinated against influenza, if the vaccine is available to them.

Once the legislative requirement relating to residential aged care facilities that requires workers to have had an influenza vaccine are no longer in place then workers in these facilities should be managed in accordance with the policy directive requirements for Category A High Risk areas. This is, workers who are unable or refuse to be vaccinated can wear a mask or be re-deployed to a lower risk area. The vaccination declaration must be signed by an appropriately trained assessor.

See Key definitions in the PD for further information. A laboratory report indicating a negative IGRA result can be signed off as compliant by an authorised immunisation assessor. If the result is positive the worker will need to be referred to a TB Service Chest Clinic for a chest x-ray and clinical review.

Full TB compliance will be granted once the TB clinical review has been attended. Health services are required to make vaccinations available to all workers, including those on a rotating roster. Your staff health unit should provide information for all employees about arrangements to access influenza vaccine. If you are a worker with specialist clinical skills i. Infected health care workers can pass the virus on to their patients before they even know they are sick. The most effective way to prevent the flu is by getting vaccinated and adopting additional preventative measures, such as proper hand hygiene and proper sneezing and coughing etiquette more information is available.

Immunisation helps health professionals reduce their risk of contracting influenza and spreading it to their patients. It also reduces the risk of you catching influenza at work and taking it home to your family. In addition, there is evidence that vaccination also reduces the severity of illness among people who are vaccinated but still get sick. Although one of the vaccine strains in the vaccine did not protect as well for the circulating A virus, the three other vaccine strains provided good protection against influenza viruses for immunised staff.

The vaccines used in Australia contain only part of the influenza virus and cannot cause infection. Common reactions to the flu shot may include soreness, redness and swelling where the vaccine was given. Occasionally other symptoms can include fever, headache and aching muscles that may last one to two days.

Wearing a mask, in conjunction with hand and respiratory hygiene, reduces the risk of influenza transmission. However, wearing a mask is still secondary to vaccination in terms of preventing the transmission of influenza. During a season with pronounced vaccine mismatch, health care workers who have been vaccinated may voluntarily wear a mask to further reduce the risk of transmission.

However, this not a requirement of this policy as there is no strong evidence to support universal wearing of masks as a preventive measure in the presence of pronounced vaccine mismatch and in the absence of an outbreak.

In addition, influenza seasons with pronounced vaccine mismatch are, fortunately, uncommon. To protect patients from influenza transmission, both vaccinated and unvaccinated staff members should consistently practice hand and respiratory hygiene and stay at home if they are experiencing influenza-like illness until symptom resolution. Influenza vaccine will be available through clinics in your workplace from April and staff in Category A High Risk positions should be vaccinated by 1 June annually.

The Chief Executive of the local health district will be reporting annually to NSW Health on compliance with the policy directive. You should ensure that your doctor or authorised nurse immuniser or authorised pharmacist vaccinator provides you with evidence of influenza vaccination so that a copy can be provided to your staff health clinic.

Vaccination remains is the best protection pregnant women and their newborn babies have against influenza. Influenza infection during pregnancy can lead to premature delivery and severe disease in the mother. Vaccination during pregnancy also reduces the risk of the baby becoming ill with influenza in the early months of life. Pregnant women can have the vaccine at any stage of pregnancy or while breastfeeding. Staff health programs can order this vaccine via the online ordering system.

Facilities will need to ensure that it is clearly labelled to distinguish it from the quadrivalent influenza vaccine. You may be trying to access this site from a secured browser on the server. You must also inform your placement contact. In order to protect yourself and your patients, NSW Health have determined that you need to be immunised against a range of specified diseases.

You may need to provide evidence both of the administration of a vaccine and of a positive response to the vaccine e. These are available from your Placement Contact. Red Cards must be completed, signed and stamped by a doctor or authorised nurse immuniser. Or refer to the policy for other options e. Between weeks after the 3 rd dose you need to get a serology test done to show that the vaccine worked.

Only if a record of vaccination is not available and cannot be reasonably obtained, you can complete and submit Appendix 9 Hepatitis B Vaccination Declaration PDF page The vaccination declaration should include details on where and when the vaccination course was administered, the vaccination schedule and why a vaccination record cannot be provided.

NSW Health staff will determine where this is acceptable evidence. You must be able to provide evidence of Hepatitis B serology showing immunity to complete a Hepatitis B Vaccination Declaration. You need to connect with your placement contact and in conjunction with NSW Health, your situation will be assessed on an individual basis as risk management plans are not available for students.

Some students will need to go on placement before they have finished their full Hep B course. Where only partial vaccination has been undertaken for Hep B you must have had at least the first dose you may be eligible for Temporary Verification. This means that you should still submit your documents to NSW Health in order to attend placements. All other specified diseases require full vaccination prior to clinical placement.

Temporary Verification lasts for 6 months and you can only receive it once.